EPISODE · Feb 2, 2023 · 16 MIN
EMERALD Ph III Study in discussion w/ Dr. Aditya Bardia (now FDA Approved)
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with the lead author, Dr. Aditya Bardia - Associate Professor at Massachusetts General Hospital - Harvard Medical School. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected]
What this episode covers
Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with the lead author, Dr. Aditya Bardia - Associate Professor at Massachusetts General Hospital - Harvard Medical School. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected]
NOW PLAYING
EMERALD Ph III Study in discussion w/ Dr. Aditya Bardia (now FDA Approved)
No transcript for this episode yet
Similar Episodes
Mar 31, 2026 ·54m
Mar 27, 2026 ·14m
Mar 24, 2026 ·42m
Mar 20, 2026 ·42m
Mar 17, 2026 ·41m
Mar 13, 2026 ·44m